11 Jan 2019 Research

Lymphoma: Understanding relapse and treatment resistance

What is this research looking at?

Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.

We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.

We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.

Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.

By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.

We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.

Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.

What could this mean for people with leukaemia?

This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.

Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution

Related posts

Leukaemia UK launches manifesto to demand better for those affected by leukaemia

13 March 2024

Leukaemia UK launches manifesto to demand better for those affected by leukaemia

Leukaemia UK has today launched its manifesto to demand better for those affected by leukaemia.    The manifesto calls on the next government to save and improve the lives of those…

Together we are changing lives – Here’s how your support is making it happen

3 July 2025

Together we are changing lives – Here’s how your support is making it happen

At this point in our advocacy journey, we wanted to share an update to you, our supporters, on everything we’ve achieved so far and what’s next as we continue to…

New campaign launches for the forgotten 500,000 families

17 October 2022

New campaign launches for the forgotten 500,000 families

Patient groups, charities and clinicians unite to raise awareness of half a million vulnerable people, many of whose lives have never returned to normal after the Covid-19 lockdown. A new…

Open letter from cancer charities to the public

18 July 2021

Open letter from cancer charities to the public

40 charities and organisations have written an open letter, urging the public to help keep vulnerable people safe as restrictions ease.